Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
erythromycin, Quantity: 250 mg
Mayne Pharma International Pty Ltd
Erythromycin
Capsule, enteric
Excipient Ingredients: povidone; monobasic potassium phosphate; lactose monohydrate; Gelatin; carbon black; sunset yellow FCF; Shellac; indigo carmine; purified water; cellacefate; erythrosine; diethyl phthalate
Oral
25
(S4) Prescription Only Medicine
MAYNE PHARMA ERYTHROMYCIN is indicated in children and adults for the treatment of the following conditions: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (group A beta haemolytic streptococci), Streptococcus pneumoniae (Diplococcus pneumoniae). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes (group A beta hemolytic streptococci), Streptococcus pneumoniae (Diplococcus pneumoniae), acute and chronic bronchitis, pneumonia. Sinusitis caused by Streptococcus pneumoniae, Streptococcus pyogenes. Otitis media due to Streptococcus pneumoniae, Streptococcus pyogenes. Respiratory tract infections due to Mycoplasma pneumonia (Eaton's agent). Skin, and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment). Bordetella pertussis: Erythromycin produces early elimination of the causative organism from the nasopharynx although the clinical course of the disease is not altered; therapeutic doses should be continued for at least 10 days. Diphtheria: As an adjunct to antitoxin infections due to Corynebacterium diphtheriae, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Infections due to Listera monocytogenes. Non-gonococcal Urethritis: Chlamydia trachomatis and Ureaplasma urealyticum have been shown to be sensitive to erythromycin and clinical studies have demonstrated its efficacy in urethritis due to these organisms. A minimum of 10 days therapy appears to be required. Chlamydia trachomatis infection (excluding Non-gonococcal urethritis): Erythromycin has been shown to be effective in the treatment of trachoma or inclusion-body conjunctivitis and pneumonia in infants caused by Chlamydia trachomatis. Campylobacter fetus (subspecies) jejuni: Infections due to this organism when antibiotic therapy is indicated. Primary syphilis caused by Treponema pallidum: Erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. In the treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the followup after therapy. Legionnaires' disease caused by Legionella pneumophila: Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prevention of initial attacks of rheumatic fever: Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group A beta - haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin allergic patients. A therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever: Penicillin or sulphonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended by the American Heart Association in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). Prevention of bacterial endocarditis: Although no controlled clinical efficacy trials have been conducted, oral erythromycin has been suggested by the American Heart Association and the American Dental Association in a regimen for prophylaxis against bacterial endocarditis in patients sensitive to penicillin who have congenital heart disease, or rheumatic or other acquired valvular heart disease when they undergo dental or surgical procedures of the upper respiratory tract. Erythromycin is not suitable prior to genitourinary or gastrointestinal tract surgery.
Visual Identification: a red/yellow gelatin capsule printed Eryc in black, filled with white spheroidal pellets; Container Type: Bottle; Container Material: HDPE; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius
Registered
2012-07-10
MAYNE PHARMA ERYTHROMYCIN CAPSULES 1 MAYNE PHARMA ERYTHROMYCIN CAPSULES CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I USING MAYNE PHARMA ERYTHROMYCIN CAPSULES? Mayne Pharma Erythromycin capsules contain the active ingredient erythromycin. They are used to treat infections in different parts of the body caused by bacteria and prevent infections in patients with a history of rheumatic disease who may be allergic to penicillin. For more information, see Section 1. Why am I using Mayne Pharma Erythromycin capsules? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE MAYNE PHARMA ERYTHROMYCIN CAPSULES? Do not use if you have ever had an allergic reaction to erythromycin or any of the ingredients listed at the end of the CMI. Do not use if you have severe liver problems. Do not use if you have ever had changes in the rhythm or rate of the heartbeat, or disturbances in your electrolyte levels. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I use Mayne Pharma Erythromycin capsules? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with Mayne Pharma Erythromycin capsules and affect how they work. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE MAYNE PHARMA ERYTHROMYCIN CAPSULES? • For treating most infections, the usual adult dose of Mayne Pharma Erythromycin capsules is one 250 mg capsule four times a day or two 250 mg capsules twice a day. For the long-term prevention of streptococcal infections in persons with a history of rheumatic heart disease and an allergy to penicillin, the usual dose is one 250 mg capsule twice a day. • Swallow the capsules whole with a full glass of water. Do not chew or crush the capsule Read the complete document
v 4.0 1 AUSTRALIAN PRODUCT INFORMATON MAYNE PHARMA ERYTHROMYCIN (ERYTHROMYCIN) CAPSULES 1. NAME OF THE MEDICINE Erythromycin 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Erythromycin is produced by a strain of _Streptomyces erythreus_ and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. Each Mayne Pharma Erythromycin capsule contains 250 mg erythromycin, comprising of enteric coated pellets of erythromycin for oral administration. The enteric coating on the pellets covers the bitter tasting erythromycin as well as protects the erythromycin from gastric acid destruction during the passage through the stomach. Mayne Pharma Erythromycin contains lactose. For the full list of excipients, see _section _ _6.1 List of Excipients_ . 3. PHARMACEUTICAL FORM Mayne Pharma Erythromycin capsules are transparent red/yellow capsules imprinted with ‘Eryc’, containing white enteric coated pellets. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Mayne Pharma Erythromycin capsules are indicated in children and adults for the treatment of the following conditions: Upper respiratory tract infections of mild to moderate degree caused by _Streptococcus _ _pyogenes_ (group A beta haemolytic _streptococci_ ), _Streptococcus pneumoniae _ _(Diplococcus pneumoniae)_ . Lower respiratory tract infections of mild to moderate severity caused by _Streptococcus _ _pyogenes_ (group A beta haemolytic _streptococci_ ), _Streptococcus pneumoniae _ _(Diplococcus pneumoniae)_ , acute and chronic bronchitis, pneumonia. Sinusitis caused by _Streptococcus pneumoniae, Streptococcus pyogenes_ . Otitis media due to _Streptococcus pneumoniae, Streptococcus pyogenes_ . v 4.0 2 Respiratory tract infections due to _Mycoplasma pneumonia_ (Eaton's agent). Skin, and skin structure infections of mild to moderate severity caused by _Streptococcus _ _pyogenes_ and _Staphylococcus aureus_ (resistant _staphylococci_ may emerge during treatment). _Bordetella pertussis_ : Erythromycin produces early elimination of the c Read the complete document